Trial Profile
Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adult T-cell leukaemia-lymphoma; HTLV-I infections
- Focus Adverse reactions; Therapeutic Use
- 02 Dec 2019 Status changed from active, no longer recruiting to completed.
- 29 Aug 2019 Results published in the Blood
- 20 Apr 2018 Planned End Date changed from 1 Oct 2018 to 30 Nov 2018.